Physician profile
Frank Kim
NPI 1902888050
$6,224.24
in general payments reported to CMS, 2019-2025
26 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $108 · 2021: $920 · 2022: $896 · 2023: $1,084 · 2024: $1,268 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,273.38 | 2019-2025 | |
| Janssen Biotech, INC. | $1,165.49 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $423.62 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $331.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.05 | 2019-2024 | Entyvio |
| Braintree Laboratories, INC. | $267.82 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $247.64 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.55 | 2019-2024 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $219.87 | 2021-2022 | |
| Celgene Corporation | $147.92 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $78.70 | 2022-2025 | Ibsrela |
| Shionogi INC | $74.66 | 2019-2020 | |
| Qol Medical, LLC | $70.42 | 2019-2023 | Sucraid |
| Daiichi Sankyo INC. | $55.07 | 2022-2025 | Injectafer |
| Allergan, INC. | $47.11 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $41.20 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $36.23 | 2019-2023 | Dificid, Zinplava |
| Ferring Pharmaceuticals INC. | $33.46 | 2019-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $33.19 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $32.34 | 2019-2022 | |
| Novo Nordisk INC | $21.23 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $19.67 | 2021 | |
| Shire North American Group INC | $17.93 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.05 | 2023 | |
| Lilly USA, LLC | $13.27 | 2023 | |
| Alfasigma USA, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.